BIOLOGIE
Loss of Lipid-Regulating Gene Fuels Prostate Cancer Spread [Johns Hopkins] The researchers say the loss of CAVIN1 in tumor cells could potentially be used as a biomarker, alerting clinicians to a risk of metastasis.
DÉPISTAGE
The technique, known as high-throughput dynamic BH3 profiling (HT-DBP) is a scaled-up version of a test created by Dana-Farber researchers that gauges how close tumor cells are to death after treatment with cancer drugs.
DÉPISTAGE - PROSTATE
Published in Urology, the new results demonstrate the GPS test is a strong independent predictor of critical outcomes in UFI-risk prostate cancer patients.
TRAITEMENTS - PRÉ-CLINIQUE
Using human cell and mouse models, City of Hope scientists demonstrate that the cancer inhibitors they’re developing could destroy acute myeloid leukemia and tumors from brain, pancreatic and breast cancers.
PHARMA
Lilly plans to present these data at a medical meeting later this year.
The late-stage trial data on Verzenio delivering a reduced risk of breast cancer recurrence or death comes earlier than expected and sets up the drug to have an expanded approval by roughly the middle of next year.
Lilly’s stock was up 13% on the news, from $141.49 to $160.45. That represents over $17 billion in added market cap value.
The results come two weeks after a rival Pfizer drug, Ibrance, failed in a similar trial, albeit in a different study population.
The win, which Evercore ISI analyst Umer Raffat called a “surprise” in a Tuesday note, marks the first for a CDK4/6 inhibitor in the so-called adjuvant setting, in which the intention with treatment is to prevent invasive disease from returning.
PHARMA - PARTENARIATS
The MAT2A program is designed for patients with tumors having MTAP gene deletion. Their other synthetic lethality programs, according to their web site, “are for patients having tumors with genetic mutations in homologous recombination deficiency, including BRCA mutations, or base excision repair, and tumors having high microsatellite instability.”
The strategic partnership includes IDEAYA’s Synthetic Lethality programs MAT2A, Pol Theta, and Werner Helicase programs, which are projected to reach clinical trials within the next three years.
Ideaya CEO Yujiro Hata said the deal validated his company’s approach to synthetic lethality. He also revealed that the alliance could see the new partners work together in yet another hot, emerging area of cancer drug research—targeted protein degradation.
PHARMA - BIOTECH
Ona raises €30M to treat metastases by blocking fat intake [Fierce Biotech] The metastasis-initiating cells expressed high levels of CD36, leading the team to explore the effect of using neutralizing antibodies to block the receptor and thereby cut the cells off from the fatty acids that may fuel their journey between organs
TRAITEMENTS - FDA, EMA,...
Ipsen receives FDA Fast Track designation for liposomal irinotecan (ONIVYDE®) as a first-line combination treatment for metastatic pancreatic cancer [Ipsen] Final analysis of the Phase 1/2 clinical study to be presented as a late-breaking virtual presentation at the ESMO World Congress on Gastrointestinal Cancer (WCGI) on July 1, 2020.
TRAITEMENTS - AMM
Jazz Pharma’s $1B bet pays off with accelerated lung cancer approval [EndPoints] Seven months after the Irish biopharma licensed PharmaMar’s small cell lung cancer drug lurbinectedin, the FDA has granted it accelerated approval.
LUTTE CONTRE LES CANCERS - COVID19
Registry tracks outcomes among thoracic cancer patients sickened by COVID-19 [Medical XPress] While the majority of those who died were hospitalized, only 9% were admitted to intensive care units, according to a study published in The Lancet Oncology. Most died from complications of COVID-19, not the progression of cancer.
‘We have a job to do’: Cancer patients and their doctors carry on with clinical trials during Covid-19 [STAT]
In cancer, the number of new patients entering Phase 2 and 3 cancer trials in the U.S. plummeted by about 46% to 48% in the last two weeks of March.
